Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 79Triple Negative Breast Neoplasms 9Stomach Neoplasms 8Inflammatory Breast Neoplasms 6Carcinoma, Hepatocellular 6Non-Muscle Invasive Bladder Neoplasms 3Esophageal Neoplasms 3Sarcoma 2Primary Breast Cancer 2Pathologic Complete Response 2Lung Neoplasms 2Carcinoma, Ductal, Breast 2Breast Neoplasms, Male 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma 1Resectable HER2-positive Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oesophago-gastric Cancer 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Unknown Primary 1Neoplasms 1Nasopharyngeal Carcinoma 1Malignant mesenchymal tumor 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Docetaxel 3Cyclophosphamide 3Paclitaxel 2Epirubicin 2Tamoxifen 1Fluorouracil 1Doxorubicin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Primary Breast Cancer × Epirubicin × Clear all
NCT04127019 2020-02-26

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Fudan University

Phase 3 Completed
2,079 enrolled
Breast

Primary Breast Cancer

NCT01049425 2019-08-14

planB

West German Study Group

Phase 3 Completed
3,198 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡